Immune reconstitution syndrome - Revision history

ClaireLewis at 17:21, 25 October 2020

2020-10-25T17:21:31Z

← Revisión anterior		Revisión del 17:21 25 oct 2020
Línea 4:		Línea 4:
	==Clinical Features==		==Clinical Features==
	*Symptoms of underlying illness within 1 week to a few months after initiating ART		*Symptoms of underlying illness within 1 week to a few months after initiating ART
	*Fever (especially with mycobacterial or cryptococcal infections)<ref>Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30(6):882–892. doi:10.1086/313809</ref>		*[[Fever]] (especially with mycobacterial or cryptococcal infections)<ref>Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30(6):882–892. doi:10.1086/313809</ref>
	*Manifestations of the underlying disease process:		*Manifestations of the underlying disease process:
	**[[Tuberculosis]]		**[[Tuberculosis]]
Línea 65:		Línea 65:
	==References==		==References==
	<references/>		<references/>
			[[Category:ID]]

2020-03-24T15:57:38Z

Clinical Features

← Revisión anterior		Revisión del 15:57 24 mar 2020
Línea 8:		Línea 8:
	**[[Tuberculosis]]		**[[Tuberculosis]]
	**[[Mycobacterium avium]]		**[[Mycobacterium avium]]
	**[[~~Cryptococcis~~]]		**[[Cryptococcus neoformans]]
	**[[Cytomegalovirus]]		**[[Cytomegalovirus]]
	**[[Progressive multifocal leukoencephalopathy]] (associated with the JC virus)		**[[Progressive multifocal leukoencephalopathy]] (associated with the JC virus)

2020-03-24T15:57:14Z

Clinical Features

← Revisión anterior		Revisión del 15:57 24 mar 2020
Línea 8:		Línea 8:
	**[[Tuberculosis]]		**[[Tuberculosis]]
	**[[Mycobacterium avium]]		**[[Mycobacterium avium]]
	**~~Cryptococcus~~		**[[Cryptococcis]]
	**[[Cytomegalovirus]]		**[[Cytomegalovirus]]
	**[[Progressive multifocal leukoencephalopathy]] (associated with the JC virus)		**[[Progressive multifocal leukoencephalopathy]] (associated with the JC virus)

2020-03-24T15:56:50Z

Clinical Features

← Revisión anterior		Revisión del 15:56 24 mar 2020
Línea 10:		Línea 10:
	**Cryptococcus		**Cryptococcus
	**[[Cytomegalovirus]]		**[[Cytomegalovirus]]
	**[[Progressive multifocal ~~leukoencephalopahthy~~]] (associated with the JC virus)		**[[Progressive multifocal leukoencephalopathy]] (associated with the JC virus)
	**[[Pneumocystis jirovecii pneumonia]]		**[[Pneumocystis jirovecii pneumonia]]
	**[[Herpes zoster]]		**[[Herpes zoster]]

2020-03-24T15:56:27Z

Clinical Features

← Revisión anterior		Revisión del 15:56 24 mar 2020
Línea 10:		Línea 10:
	**Cryptococcus		**Cryptococcus
	**[[Cytomegalovirus]]		**[[Cytomegalovirus]]
	*[[JC virus]]		**[[Progressive multifocal leukoencephalopahthy]] (associated with the JC virus)
	*[[Pneumocystis jirovecii pneumonia]]		**[[Pneumocystis jirovecii pneumonia]]
	*[[Herpes zoster]]		**[[Herpes zoster]]
	*[[Hepatitis B]]		**[[Hepatitis B]]
	*[[Leishmaniasis]]		**[[Leishmaniasis]]
	*[[Kaposi sarcoma]]		**[[Kaposi sarcoma]]

	==Differential Diagnosis==		==Differential Diagnosis==

2020-03-24T15:43:39Z

2020-03-24T15:41:50Z

Disposition

← Revisión anterior		Revisión del 15:41 24 mar 2020
Línea 48:		Línea 48:

	==Disposition==		==Disposition==
			*Disposition depends on severity of the immune response as well as the specific underlying disease process. Consider admission if unstable, poor follow-up, or severe illness.

	==See Also==		==See Also==

2020-03-24T15:38:26Z

Management

← Revisión anterior		Revisión del 15:38 24 mar 2020
Línea 43:		Línea 43:

	==Management==		==Management==
			*Continue ART
			*Treatment of underlying opportunistic infection
			*[[Glucocorticoids]] may be indicated as adjunct therapy for severe cases

	==Disposition==		==Disposition==

2020-03-24T15:36:57Z

Differential Diagnosis

← Revisión anterior		Revisión del 15:36 24 mar 2020
Línea 18:		Línea 18:

	==Differential Diagnosis==		==Differential Diagnosis==
			*Progression of [[HIV]]/[[AIDS]]
			*Antimicrobial resistance
			*Medication noncompliance
			*Development of new opportunistic infection rather than recrudescence
			*Drug toxicity

	==Evaluation==		==Evaluation==

2020-03-24T15:35:40Z

Clinical Features

← Revisión anterior		Revisión del 15:35 24 mar 2020
Línea 4:		Línea 4:
	==Clinical Features==		==Clinical Features==
	*Symptoms of underlying illness within 1 week to a few months after initiating ART		*Symptoms of underlying illness within 1 week to a few months after initiating ART
	*Fever (especially with mycobacterial or cryptococcal infections)		*Fever (especially with mycobacterial or cryptococcal infections)<ref>Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30(6):882–892. doi:10.1086/313809</ref>
	*Manifestations of the underlying disease process:		*Manifestations of the underlying disease process:
	**[[Tuberculosis]]		**[[Tuberculosis]]

← Revisión anterior		Revisión del 15:43 24 mar 2020
Línea 51:		Línea 51:

	==See Also==		==See Also==
			*[[HIV]]
			*[[AIDS]]
			*[[Mycobacterium tuberculosis]]
			*[[Mycobacterium avium]]
			*[[Cytomegalovirus]]
			*[[Cryptococcus neoformans]]
			*[[Pneumocystis jirovecii]]
			*[[Herpes simplex virus]]

	==External Links==		==External Links==